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Abstract
Purpose: Palliative care is increasingly viewed as a necessary
component of cancer care, especially for patients with advanced
disease. Rigorous clinical trials are thus needed to build the pal-
liative care evidence base, but clinical research—especially par-
ticipant recruitment—is difficult. Major barriers include (1) patient
factors, (2) “gatekeeping,” and (3) ethical concerns. Here we
discuss an approach to overcoming these barriers, using the
Palliative Care Trial (PCT) as a case study.
Patients and Methods: The PCT was a 2  2  2 factorial
randomized controlled trial (RCT) of different service delivery
models to improve pain control in the palliative setting. It used a
recruitment protocol that fused evidence-based strategies with
principles of “social marketing,” an approach involving the sys-
tematic application of marketing techniques. Main components
included (1) an inclusive triage algorithm, (2) information booklets
targeting particular stakeholders, (3) a specialized recruitment
nurse, and (4) standardization of wording across all study com-
munications.
Results: From an eligible pool of 607 patients, the PCT en-
rolled 461 patients over 26 months. Twenty percent of patients
referred to the palliative care service were enrolled (76% of those
eligible after screening). Several common barriers were mini-
mized; among those who declined participation, family disinter-
est was uncommon (5%), as was the perception of burden
imposed (4%).
Conclusion: Challenges to clinical trial recruitment in palliative
care are significant but not insurmountable. A carefully crafted
recruitment and retention protocol can be effective. Our experi-
ence with designing and deploying a social-marketing–based
protocol shows the benefits of such an approach.
Introduction
Palliative care is increasingly viewed as a necessary component
of comprehensive cancer care, especially for patients with ad-
vanced, incurable disease.1 Caring for this highly symptomatic
population will require further development of the palliative
care evidence base; rigorous clinical trials in palliative care are
needed. Clinical research in this arena, however, can be diffi-
cult. Recruitment and retention challenges often impede the
development and successful completion of clinical trials in ad-
vanced cancer and palliative care.2 Large randomized controlled
trials (RCTs), in particular, have historically been considered
unfeasible in this setting. This article provides a brief overview
of the recruitment challenges unique to palliative care, and
presents examples from the Palliative Care Trial (PCT) to high-
light strategies to overcome and address these barriers in the
setting of a large study.
The 2004 US National Consensus Project for Quality Pal-
liative Care clinical practice guidelines state, “The randomized
controlled trial has been difficult to carry out in the field of
palliative care—being too intrusive and time consuming to be
performed with very sick persons or with families under great
stress.”3 The most successful recruitment rates previously de-
scribed in the palliative care literature leave considerable room
for improvement. Ling et al4 recruited 362 participants receiv-
ing palliative care for cancer into 23 different clinical trials over
a 4-year period. Jordhøy et al5 recruited 434 participants over a
period initially set at 24 months, which was then extended to 33
months in order to reach the required sample size. Both of these
studies invested a great deal of time into monitoring and adapt-
ing recruitment efforts. It is uncommon for palliative care clin-
ical trials to enroll the required number of participants in the
given time frame6; the recruitment period often needs to be
extended,7 additional sites engaged,8 or recruitment strategies
improved.9
There are numerous barriers to palliative care clinical trials
accrual, which are discussed at length elsewhere.10 Generally
speaking, these barriers can be distilled into three domains: (1)
patient issues, (2) “gatekeeping,” and (3) ethical issues. Patient
issues include frailty, limited life expectancy or prognostic un-
certainty, competing demands, fatigue, and the reminder of
impending death. Evidence suggests, however, that patients are
often quite interested in research participation and may even
benefit from it.11 Gatekeeping occurs when clinicians and/or
caregivers make assumptions that research is burdensome or
upsetting, that it is of no benefit to the patient, that it would be
intrusive, that it could yield false hope, or that it is unethical;
prior work shows this to be a common problem.12 Ethical con-
cerns relate to patients’ increased vulnerability near the end of
life, a decreased capacity to consent in some situations, and
concerns about clinical equipoise, as some providers already
believe they know and use the most optimal methods of pro-
viding care at the end of life. These ethical concerns are often
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unjustified but rarely insurmountable, and we have discussed
them elsewhere.13 Thus we focus here on the patient-related
issues and gatekeeping concerns, using the recruitment protocol
of the PCT to highlight several effective approaches to these
common problems. It is important to note that the eligibility
criteria for many palliative care studies may significantly limit
the pool of potential participants, so careful planning in this
area is key. Because this issue is discussed at length elsewhere, we
do not make it a focus of discussion here.14
Patients and Methods
Trial Design
The PCT was a 2  2  2 factorial RCT designed to test
different service delivery models to improve pain control in the
palliative care setting; it was conducted in Adelaide, South Aus-
tralia, from 2001 to 2004. Patients were randomly assigned
three times, to (1) individualized interdisciplinary case confer-
ence with their general practitioner (GP) versus control, (2)
educational outreach visitation to GPs about pain management
versus control, and (3) structured educational visitation for pa-
tients and caregivers about pain management versus control.
Main outcome measures included the Australia-modified Kar-
nofsky Performance Status Score (AKPS), pain scores 60 days
after random assignment, and number of hospitalizations. Tar-
get enrollment was 460 patients over a 26-month period. Eli-
gible participants were adult, had been referred to the palliative
care service, had experienced any form of pain in the preceding
3 months, were mentally competent at enrollment as docu-
mented by a Folstein Mini-Mental State Examination score
 24,15 and had a GP willing to participate in the trial. If not
capable of doing so themselves, participants could have a legal
health care proxy or a GP-identified caregiver provide informed
consent,16 though both participant/proxy and GP consent were
required for enrollment. Exclusion criteria were (1) patient ex-
pected to die within 48 hours of referral, and (2) patient resided
outside the geographic service area.
The PCT successfully recruited and enrolled 461 patient
participants and their physicians over 26 months. The 461
patients enrolled represent 20% of the 2,305 patients referred
to the palliative care service, of whom 607 were eligible for
enrollment. The main reasons that people declined participa-
tion during the recruitment visit were as follows: “too sick” (40
of 107 reasons cited; 37%), “too busy” (37; 6%), “too stressed
or overwhelmed” (15; 14%), “palliative care service involve-
ment not wanted” (6; 6%), “not interested” (6; 6%), “family
not interested” (5; 5%), and “trial too burdensome” (4; 4%).
The results, recently published,17 showed that case confer-
encing reduced hospital admissions by 26% compared with the
control condition. This intervention was also associated with
maintenance of performance status as measured by AKPS (57.3
v 51.7, P  .0368). Furthermore, among patients with declin-
ing functional status (AKPS  70), case conferencing and ed-
ucational intervention also appeared to better maintain
performance status (55 v 46.5, P  .0143; and 54.7 v 46.8, P 
.0206, respectively). Education of GPs did not appear to affect
the measured outcomes.
Development of a Tailored Recruitment Plan
Because difficulty with accrual had been widely documented as
a barrier to similar trials preceding the PCT, a recruitment-
retention protocol was developed, which aimed to fuse evi-
dence-based strategies with principles of social marketing.
Social marketing is defined as the systematic application of
marketing techniques aimed at achieving a particular social
good.18 After an initial systematic review of the literature re-
garding large trial recruitment strategies—both in general, and
in oncology, palliative care, cardiology, and health services re-
search—study resources were developed, including a triage al-
gorithm, information booklets, and recruitment scripts. This
included four key steps and components: (1) developing a triage
algorithm, (2) preparing information books targeted to stake-
holders, (3) hiring a specialized recruitment nurse, and (4) stan-
dardization of wording across study communications. Each
component was designed for ease of use, minimization of bur-
den on nonstudy personnel, and likelihood of facilitating pa-
tient control over the outcome. As such, the triage algorithm
was very inclusive; a different information booklet was devel-
oped specifically for caregivers (all at a fifth-grade reading level),
and key messages were pilot tested and role-played. See the Data
Supplements to view the original screening algorithm, patient
information booklet, and general study brochure.
These key elements aimed to increase screening and enroll-
ment efficiency (Figure 1). For example, recruitment was facil-
itated by broad eligibility criteria; 79% of those screened were
deemed eligible for inclusion. The literature highlights restric-
tive eligibility criteria as one of the main causes of nonpartici-
pation in clinical trials.19 In addition, the appointment of a
dedicated recruitment nurse also supported recruitment in sev-
eral key ways, as demonstrated in other successful trials.4,20
Having a dedicated recruitment nurse ensures consistent
knowledge of study quality control measures, appropriate train-
ing, strong interpersonal skills, and targeted supplemental com-
munication training when necessary. The presence of a
recruitment nurse also relieved clinical nurses of the recruit-
ment burden often posed by studies, typically a significant bar-
rier to recruitment.21 Separating recruitment from clinical care
also reduced the pressure on potential participants to consent in
order to please their doctors or nurses; this motivation is a major
ethical concern for conducting studies with people in a depen-
dent relationship.22
Triage algorithm. The PCT’s referral strategies were designed
to maximize the number of potential participants during initial
screening. Study staff notified potential referring physicians in
advance, using very broad eligibility criteria so they would not
have to remember complex rules. Ensuring that clinicians could
focus on referring patients to the study, rather than having to
know complex eligibility criteria and worry about doing screen-
ing themselves, was key to the success of this endeavor. More
detailed screening was completed by study personnel, to pre-
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vent gatekeeping and to decrease burden on referrers. Incorpo-
ration of research screening into the palliative care service’s
regular triage process maximized the number of patients
screened. Clinical triage nurses, explaining that they were not
part of the trial staff, first gauged patients’ interest and asked
potentially eligible patients for permission for trial staff to con-
tact them. Study investigators were concerned that the offer to
decline contact by the trial staff would decrease recruitment
opportunities; in fact, of 1,948 people screened, 941 (48%) did
decline contact. However, the group who permitted contact by
trial staff were much more willing to participate in the study
(500 of 607; 82%), thereby saving valuable recruitment nurse
effort.
Social marketing application. Implemented marketing strategies
included involving clinical staff in study procedure develop-
ment, multiple presentations to clinic staff, branding materials
to promote recognition, and facilitating motivational meetings
for stakeholders. Relationship building played an important
role in achieving buy-in for the recruitment process. A weekly
trial-sponsored coffee hour demonstrated commitment to im-
proving trial procedures in response to the clinical team’s con-
cerns. Focus groups provided insight into any problems and
demonstrated the positive impact of a coordinated research pro-
gram on a large palliative care service. Consultation with med-
ical stakeholders, including consultants and GPs, increased
awareness of the trial throughout the study period and facili-
tated recruitment discussions between research staff and stake-
holders. Clinical staff involvement in steering committees,
regular morning discussions about study progress and other
protocols in development, and regular focus groups to monitor
burden of research on clinical operations provided constant
surveillance of perceptions and attitudes about the study.
Per principles of social marketing, interaction with the target
audience was carefully structured to optimize outcomes; spe-
cific messaging was established, aimed at ensuring that patients
maintained control, thereby minimizing gatekeeping. For ex-
ample, leaving a blank study withdrawal form with participants
and families at the time of consent likely contributed to the
study’s high consent rate. This practice provided clear assurance
that withdrawal was allowed at any time, without compromis-
ing ongoing care.
In order to further minimize issues of gatekeeping, each re-
cruitment visit also involved caregivers and was conducted in
patients’ homes when possible. This ensured that caregivers
were adequately informed and received the same key messages
as the patients. A focus on fully educating patients, caregivers,
and clinical staff about the study, as well as its purposes and





Proxy and GP consenting procedures
Outreach and education
Address reluctance to recruit
To examine the quality of activities
Participant and caregiver information
booklets and simplified consent documents
To ensure that potential participants and their families/
caregivers fully understood all aspects of the study
To increase recruitment rates by addressing fears and
concerns of patients and families/caregivers
To ensure that all stakeholders were fully informed about
the study; to increase their involvement in the study
To increase clinical staff and family involvement in 
the study; to minimize gatekeeping
To increase screening rates of new referrals 
to the palliative care service
To ensure that participants in the study were comparable
to the general population from which they were drawn; to
maximize the number of potentially eligible patients
To ensure that participants received, in a consistent and
thorough manner, all information needed to make an
informed decision regarding participation in the study
To ensure that patients did not perceive the study to 
be part of their clinical care; to reduce the burden 
on clinical staff
To increase the likelihood that the study was representative
of the palliative care service population; to increase
participation among GPs whose patients had consented
To ensure that the study would not have an impact on
participants’ clinical care; to maintain stable recruitment
rates over the recruitment period
Plans for concurrent clinical activities 
and staff time off
Continuous monitoring and 
quality assurance
Role-play training for recruitment and
enrollment visits and standardized
wording for key messages
Key messages of the recruitment visit
based on known barriers to palliative
care research
Reason for Inclusion
Figure 1. Successful evidence-based recruitment strategies used in the Palliative Care Trial protocol. GP, general practitioner.
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building trust among clinical staff and caregivers, which also
decreased gate-keeping.
Previously scripted messages intended to ensure consistency
were modified over time in response to the particular needs and
concerns of patients and their loved ones (eg, the ability to
withdraw was important, so this was stated upfront in a clear
fashion). All recruitment interactions were scripted and fre-
quently role-played to ensure consistency and quality. Use of
standardized wording, together with extensive role-playing, en-
sured that all potential participants received a consistent and
accurate message throughout recruitment.23 The role-playing
highlighted potential difficulties and led to problem solving.
Key messages are highlighted in Table 1. In addition to com-
munication skills, all study staff were also trained in research
ethics.
Results
This strategic program of social marketing resulted in a favor-
able recruitment and retention outcome as compared with
other published experiences in palliative care clinical trials.
Overall, 20% of patients referred to the palliative care service
were ultimately enrolled onto the study, representing  75% of
the eligible population. Furthermore, several common barriers
were minimized; among those who declined participation, fam-
ily disinterest was uncommon (5%), as was any perception of
excessive burden imposed by the study (4%). The most com-
mon reason for declining participation was that patients felt
“too sick” (37%).
Discussion
This study demonstrates that, with the use of a multicompo-
nent, evidenced-based recruitment protocol that addresses key
barriers to research in palliative care, large palliative care RCTs
can accrue sufficient samples. Key features of the demonstrated
recruitment protocol were a triage algorithm, broad eligibility
criteria, a dedicated recruitment nurse, simplified consent doc-
uments and information booklets, carefully planned visits that
included standardized wording for key messages, practicing
through role-plays, well-defined consenting procedures encom-
passing proxy and GP scenarios, integration with clinical ser-
vices, plans for staff relief, focused outreach, public/provider
education, plans to address gatekeeping, and continuous mon-
itoring and quality assurance (Figure 1). These strategies could
transfer readily to other disciplines that experience difficulties
in recruitment, such as geriatrics, rehabilitation, and pediatrics.
This approach was subsequently used in the dyspnea trial,
which recruited 239 palliative care patients to a randomized,
double-blind trial from 2006 to 2008,24 and it is now consid-
ered the standard approach for clinical trials conducted in the
Australian Palliative Care Clinical Studies collaborative re-
search network. It was also implemented in a study investigat-
ing the efficacy of alvimopan in the treatment of constipation;
this study initially had poor enrollment, so a revised recruit-
ment protocol was developed, using principles of social market-
ing similar to those used in the PCT.25 This quickly resulted in
a significant increase in the enrollment rate and successful com-
pletion of the study. (Figure 2). Importantly, for each of these
studies, the full set of recruitment solutions was tailored and






























Figure 2. Impact of the implementation of a revised recruitment plan on
increased referrals to the alvimopan study.
Table 1. Key Messages Highlighted During the Home Recruitment Visit
1. The purpose of this research is to improve the care of people with life-limiting illness. The results may or may not benefit you, but hopefully they will improve the
care of people who need palliative services in the future.
2. Participation in the trial is voluntary. If you choose not to take part in the trial, the care that you will receive will be the same as the care patients have received in
the past, and you will not be compromised by not being in the trial.
3. We recognize that participating in a research study can be burdensome. We have tried to minimize that burden by doing the following:
• Limiting paper questionnaires and having your nurse collect the information from you in person
• Having your nurse collect your information during normal clinical visits
• Conducting the clinical visits in the place of your choosing–eg, home, hospital, clinic
• Asking your health care provider to send us the health information that they have about you stored in their electronic databases, so that you don’t have to
repeat that information.
4. Randomization can be a confusing concept. It is a bit like drawing a number out of a hat* where you are randomly assigned to one of the care groups in the trial.
The routine care group is the same as the care you would receive if you were not in the trial.
5. You can withdraw at any time.
6. Because your doctor is an important person in your care and he or she will need to participate in the interventions, we are asking your doctor to agree to
participate in the study as well. Once you sign the consent form, we will contact your doctor to do the same.
(*) Patients taught us that random assignment should never be described as a coin flip. Change the locus of control from something that someone else does to you (eg, coin
flip) to a situation in which you control your own destiny (eg, drawing out of a hat, lucky dip). Patients understand that these are all random chance.
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honed for the specific trial; sometimes all of the solutions were
used, and at other times, we focused on practically feasible
aspects such as development of consistent key messaging, role-
plays, and recruitment materials. Practicality is key; the process
does not need to be extravagant, just well thought out, based on
best evidence, practiced and consistent.
Cost
The application of social marketing principles need not be ex-
pensive. The majority of its key elements are effectively free,
consisting of carefully constructed messaging and materials that
ensure consistency in communication about the study. Role-
plays require little time but result in further improvements in
messaging consistency and efficacy. Though the PCT used a
specialized recruitment nurse to facilitate screening, this is not
an essential component of a successful application of social
marketing principles to clinical research. In applying these prin-
ciples to several studies to date, we have found them to be
remarkably effective and important, regardless of study size,
design, or funding.
Conclusions
Research study recruitment and retention is a particular chal-
lenge in palliative care trials. This challenge, however, is not an
insurmountable one, and is worth pursuing in order to build
the palliative care evidence base and advance the science of the
field. A carefully crafted recruitment and retention protocol is
of particular importance in the successful conduct of clinical
trials in palliative care populations. Our experience with design-
ing and deploying a social marketing–based protocol in the
PCT shows the benefits of such an approach. This approach is
more regimented and time consuming but results in more pa-
tient control and reduces issues of gatekeeping, whereby pa-
tients who might be interested in participating never have the
opportunity as a result of biases on the part of their caregivers or
physicians. Repeated refinement of these protocols is necessary,
as each trial has different barriers and each patient population
has different needs.
Authors’ Disclosures of Potential Conflicts of Interest
Although all authors completed the disclosure declaration, the following
author(s) and/or an author’s immediate family member(s) indicated a
financial or other interest that is relevant to the subject matter under
consideration in this article. Certain relationships marked with a “U” are
those for which no compensation was received; those relationships
marked with a “C” were compensated. For a detailed description of the
disclosure categories, or for more information about ASCO’s conflict of
interest policy, please refer to the Author Disclosure Declaration and the
Disclosures of Potential Conflicts of Interest section in Information for
Contributors.
Employment or Leadership Position: Amy P. Abernethy, American
Academy of Hospice and Palliative Medicine (C), Advoset (C), Orange
Leaf Associates LLC (C) Consultant or Advisory Role: Amy P. Ab-
ernethy, Novartis (C), Bristol Myers Squibb (C), Pfizer (C) Stock Own-
ership: None Honoraria: Amy P. Abernethy, Novartis, Pfizer
Research Funding: Thomas W. LeBlanc, Junior Career Development
Award from the National Palliative Care Research Center; Amy P. Ab-
ernethy, National Center for Advancing Translational Sciences, National
Cancer Institute, National Institutes of Health, Agency for Healthcare
Research and Quality, Robert Wood Johnson Foundation, Biovex,
DARA, Helsinn, MiCo, Dendreon, Pfizer, Bristol Meyers Squibb, Genen-
tech Expert Testimony: None Patents, Licenses or Royalties:
None Other Remuneration: None
Author Contributions
Conception and design: Thomas W. LeBlanc, David C. Currow,
Amy P. Abernethy
Financial support: Amy P. Abernethy
Administrative support: Amy P. Abernethy
Collection and assembly of data: Thomas W. LeBlanc, David C.
Currow, Amy P. Abernethy
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Corresponding author: Amy P. Abernethy, MD, Box 3436, Duke University
Medical Center, Durham, NC 27710; e-mail: amy.abernethy@duke.edu.
DOI: 10.1200/JOP.2013.000996; published online ahead of print
at jop.ascopubs.org on October 15, 2013.
References
1. Smith TJ, Temin S, Alesi ER, et al: American Society of Clinical Oncology
provisional clinical opinion: The integration of palliative care into standard oncol-
ogy care. J Clin Oncol 2012 30(8):880-887. doi: 10.1200/JCO. 2011.38.5161.
Epub 2012 Feb 6
2. Rinck G, Kleijnen J, Van den Bos TG, et al: Trials in palliative care. BMJ
310:598-599, 1995
3. National Consensus Project for Quality Palliative Care: Clinical Practice Guide-
lines for Quality Palliative Care. New York, NY: National Consensus Project for
Quality Palliative Care, 2004; page 42
4. Ling J, Rees E, Hardy J: What influences participation in clinical trials in pallia-
tive care in a cancer centre? Eur J Cancer 36:621-626, 2000
5. Jordhøy MS, Kaasa S, Fayers P, et al: Challenges in palliative care research;
recruitment, attrition and compliance: Experience from a randomized controlled
trial. Palliat Med 13:299-310, 1999
6. Hollis JF, Satterfield S, Smith F, et al: Recruitment for phase II of the Trials of
Hypertension Prevention. Effective strategies and predictors of randomization.
Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann
Epidemiol 5:140-148, 1995
7. Chang BH, Hendricks AM, Slawsky MT, et al: Patient recruitment to a random-
ized clinical trial of behavioral therapy for chronic heart failure. BMC Med Res
Methodol 4:8, 2004
8. Agras WS, Marshall G: Recruitment for the Coronary Primary Prevention Trial.
Clin Pharmacol Ther 25:688-690, 1979
9. Benedict G: LRC Coronary Prevention Trial: Baltimore. Clin Pharmacol Ther
25:685, 1979
10. Fischer DJ, Burgener SC, Kavanaugh K, et al: Conducting research with
end-of-life populations: Overcoming recruitment challenges when working with
clinical agencies. Appl Nurs Res 25:258-263, 2012
11. White C, Hardy J: What do palliative care patients and their relatives think
about research in palliative care?-A systematic review. Support Care Cancer
18:905-911, 2010
12. White C, Gilshenan K, Hardy J: A survey of the views of palliative care health-
care professionals towards referring cancer patients to participate in randomized
controlled trials in palliative care. Support Care Cancer 16:1397-1405, 2008
13. LeBlanc TW, Wheeler JL, Abernethy AP: Research in end-of-life settings: An
ethical inquiry. J Pain Palliat Care Pharmacother 24:244-250, 2010
14. Currow DC, Shelby-James TM, Agar M, et al: Planning phase III multi-site
clinical trials in palliative care: The role of consecutive cohort audits to identify
potential participant populations. Support Care Cancer 18:1571-1579, 2010
15. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical
method for grading the cognitive state of patients for the clinician J Psychiatr Res
12:189-198, 1975
Palliative Care Clinical Trials Recruitment
NOVEMBER 2013 • jop.ascopubs.org 281Copyright © 2013 by American Society of Clinical Oncology
16. Masso M, Dodds S, Fildes D, et al: Ethical Research in Palliative Care: A Guide
Through the Human Research Ethics Committee Process. Canberra, Australia,
Commonwealth of Australia Department of Health and Ageing, 2004, pp 1-31
17. Abernethy AP, Currow DC, Shelby-James T, et al: Delivery strategies to
optimize resource utilization and performance status for patients with advanced
life-limiting illness: Results From the “Palliative Care Trial” [ISRCTN81117481].
J Pain Symptom Manage pii: S0885-3924(12)00274-6. [epub ahead of print on
October 23, 2012]
18. Etkin CD, Farran CJ, Barnes LL, Shah RC: Recruitment and enrollment of
caregivers for a lifestyle physical activity clinical trial. Res Nurs Health 35:70-81,
2012 Feb
19. Gotay CC: Accrual to cancer clinical trials: Directions from the research liter-
ature. Soc Sci Med 33:569-577, 1991
20. Lovato LC, Hill K, Hertert S, et al: Recruitment for controlled clinical trials:
Literature summary and annotated bibliography. Control Clin Trials 18:328-352,
1997
21. Hudson P, Aranda S, McMurray N: Randomized controlled trials in palliative
care: Overcoming the obstacles: Int J Palliat Nurs 7:427-434, 2001
22. Karim K: Conducting research involving palliative patients. Nurs Stand 15:34-
36, 2000
23. Kiev A: Management of clinical trials with new medications for cocaine de-
pendence and abuse. Natl Inst Drug Abuse Res Monogr Ser 175:96-117, 1997
24. Abernethy AP, McDonald CF, Frith PA, et al: Effect of palliative oxygen versus
room air in relief of breathlessness in patients with refractory dyspnoea: A double-
blind, randomised controlled trial. Lancet 376:784-793, 2010
25. Abernethy AP, Currow DC, Wurzelmann J, et al: Enhancing enrollment in
palliative care trials: Key insights from a randomized, placebo-controlled study.
J Support Oncol 8:139-144, 2010
STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)
1. Publication title: JOURNAL OF ONCOLOGY PRACTICE.
2. Publication no.: 1554-7477.
3. Filing date: October 1, 2013.
4. Issue frequency: 6 times/year; Bimonthly
5. No. of issues published annually: 6.
6. Annual subscription price: $50.00.
7. Complete mailing address of known office of publication: 2318 Mill Road, Suite 800, Alexandria, VA 22314-4609.
8. Complete mailing address of the headquarters or general business offices of the publisher: 2318 Mill Road, Suite 800, Alexandria, VA
22314-4609.
9. Full names and complete mailing addresses of publisher, editor, and managing editor: Publisher: David Sampson, Publisher, Journal of
Oncology Practice, 2318 Mill Road, Suite 800, Alexandria, VA 22314-4609. Editor: John V. Cox, DO, MBA, FACP, Editor-in-Chief,
Journal of Oncology Practice, Texas Oncologist Methodist, 3555 West Wheatland Road, Dallas, TX 7523-3461. Managing Editor:
Kenneth G. Kornfield, Managing Editor, Journal of Oncology Practice, 2318 Mill Road, Suite 800, Alexandria, VA 22314-4609.
10. Owner: American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314-4609.
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or
other securities: None.
12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
13. Publication title: JOURNAL OF ONCOLOGY PRACTICE.
14. Issue date for circulation data: Volume 9, Issue 5 (September 2013).
15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total no. copies (net press run), 22,084. (b)
Paid and/or requested circulation: (1) Paid/requested outside-county mail subscriptions stated on Form 3541 (include advertiser’s proof and
exchange copies): 16,513; (2) Paid in-county subscriptions stated on Form 3541 (include advertiser’s proof and exchange copies): N/A; (3) Sales
through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution: 64; (4) Other classes mailed through the USPS:
N/A. (c) Total paid and/or requested circulation (sum of 15b (1), (2), (3), and (4)): 16,577. (d) Free distribution by mail (samples, complimentary,
and other free): (1) Outside-county as stated on form 3541: 2,677; (2) In-county as stated on form 3541: N/A; (3) Other classes mailed through
the USPS: N/A; (4) Free distribution outside the mail (carriers or other means): 355. (e) Total free distribution (sum of 15d (1), (2), (3) and (4)):
3,032. (f) Total distribution (sum of 15c and 15e): 19,609. (g) Copies not distributed: 2,475. (h) Total (sum of 15f and 15g): 22,084. (i) Percent
paid and/or requested circulation (15c/15f x 100): 85%. Actual no. copies of single issue published nearest to filing date: (a) Total no. copies (net
press run): 23,868. (b) Paid and/or requested circulation: (1) Paid/requested outside-county mail subscriptions stated on Form 3541 (include
advertiser’s proof and exchange copies): 19,052; (2) Paid in-county subscriptions stated on Form 3541 (include advertiser’s proof and exchange
copies): N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution: 76; (4) Other classes mailed
through the USPS: N/A. (c) Total paid and/or requested circulation (sum of 15b(1), (2), (3), and (4)): 19,128. (d) Free distribution by mail
(samples, complimentary, and other free copies): (1) Outside-county as stated on Form 3541: 652; (2) In-county as stated on Form 3541: N/A; (3)
Other classes mailed through the USPS: N/A; (4) Free distribution outside the mail (carriers or other means): 355. (e) Total free distribution (sum
of 15d (1), (2), (3) and (4)): 1,007. (f) Total distribution (sum of 15c and 15e): 20,135. (g) Copies not distributed: 3,733. (h) Total (sum of 15f and
15g): 23,868. (i) Percent paid and/or requested circulation (15c/15f x 100): 95%.
16. Total circulation includes electronic copies. Report circulation on PS Form 3526-X worksheet. N/A.
17. This Statement of Ownership will be printed in Volume 9, Issue 6 (November 2013).
18. I certify that the statements made by me above are correct and complete.
David Sampson, Publisher
LeBlanc et al
282 JOURNAL OF ONCOLOGY PRACTICE • VOL. 9, ISSUE 6 Copyright © 2013 by American Society of Clinical Oncology
Copyright of Journal of Oncology Practice is the property of American Society of Clinical
Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv
without the copyright holder's express written permission. However, users may print,
download, or email articles for individual use.
